The development of a vaccine against human cytomegalovirus (HCMV) is a public health priority, as the virus globally causes serious consequences such as increased mortality in immunosuppressed individuals and severe neurological sequelae in newborns, such as hearing loss and mental retardation. A large number of vaccines for cytomegalovirus have been tested in preclinical and clinical research. However, currently, there is no approved vaccine, and therapy is aimed at suppressing the virus and reducing infec tion symptoms. The reason for this is partly due to the fact that the humoral response to cytomegalovirus infection has not been sufficiently investigated. Infection with murine cytomegalovirus (MCMV) is the most commonly used model for human cytomegalovir us infection. Females, 8 12 weeks old, immunized with the wild type virus (WT MCMV), along with their offspring, were used for this thesis, while neonatal mice were infected with different virus strains and different viral doses. The virus titer was determ ined using the plaque assay, while the neutralization capacity was determined using the neutralization assay in the presence of immune serum or serum from non immunized animals. Phenotypic analysis of the expression of MHC molecules on microglia was conduc ted using a flow cytometer. The results of this thesis show the effective neutralization of different variants of murine cytomegalovirus by antibodies transferred from a mother infected with the wild type virus, which results in the inhibition of viral rep lication in different organs. Further research is required to better understand the role of antibodies in preventing the spread of the virus, their long term effectiveness against different variants, and to correlate results obtained in mouse models and clinical studies.